To keep up to date with news from this category use our
Diamyd Technology Advances with US $ 1.84 Million Grant
November 10, 2009--Diamyd Inc, Pittsburgh, PA, USA, a wholly-owned subsidiary of Diamyd Medical, Stockholm Sweden, announces today that the United States Department of Veterans Affairs (VA) has awarded a $1.84 million...
Cerimon Pharmaceuticals Acquires European Rights to Topical Diclofenac Patch Cerimon Also Completes Enrollment of Phase 3 Diclofenac Patch Studies in Acute Pain Company Also Receives Notice of Allowance for Key US Patent Application
SOUTH SAN FRANCISCO, Calif. -November 10, 2009 - Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in...
University of Cambridge and Life Technologies Collaborate on Landmark High Throughput Sequencing Hub in United Kingdom
CARLSBAD, Calif.-- November 10, 2009-- The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research studies in key...
Opexa Therapeutics Reports Third Quarter 2009 Financial Results and Corporate Update
THE WOODLANDS, Texas--November 04, 2009---Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended...
Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
NOVATO, Calif., Nov. 4, 2009 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be...
BIOLASE Introduces the Diolase 10(TM) Diode Laser for Pain Management, Therapeutic Applications
IRVINE, CA, Nov 03, 2009 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced the launch of the Diolase 10(TM) Diode Laser for therapeutic applications, including...
Retigabine Regulatory Update
Monday 02 November 2009, London UK and California US -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application with the US Food and...
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers
November 02, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and...
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
October 30, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the...
Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis
Vienna, Austria, October 30, 2009 - Intercell AG (VSE: ICLL) today announced that the Health Canada granted product approval for IXIARO
MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
MOUNTAIN VIEW, Calif., October 29, 2009 -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's...
Pain Therapeutics Reports Third Quarter 2009 Results
SAN MATEO, Calif., Oct. 29, 2009 -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today reported financial results for the quarter ended September 30, 2009.
ELEKTA'S RADIOSURGERY SOLUTIONS ON CENTER STAGE AT 2009 CONGRESS OF NEUROLOGICAL SURGEONS ANNUAL MEETING EXTEND RECEIVES FDA 510(K) CLEARANCE
Stockholm, Sweden, October 23, 2009 -- At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand...
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
SOUTH SAN FRANCISCO, Calif. & NEW YORK-- October 23, 2009-- Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated...
Apotex to Distribute Important Transdermal System for Management of Chronic Pain in the U.S. Market
Weston, FL -October 20, 2009 Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's...
Icagen Describes Progress in Its Collaboration With Pfizer to Identify Selective Sodium Channel Inhibitors
RESEARCH TRIANGLE PARK, N.C., October 19, 2009 -- Icagen, Inc. (Nasdaq:ICGN) today announced that data related to its collaboration with Pfizer focused on certain sodium channels for the treatment of pain and related...
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...
Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia
MENLO PARK, Calif.--Oct. 5, 2009-- Depomed, Inc. (NASDAQ:DEPO) today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
